Review



shox2 polyclonal antibody  (Bioss)


Bioz Verified Symbol Bioss is a verified supplier
Bioz Manufacturer Symbol Bioss manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Bioss shox2 polyclonal antibody
    siRNA target sequences.
    Shox2 Polyclonal Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 90/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/shox2 polyclonal antibody/product/Bioss
    Average 90 stars, based on 2 article reviews
    shox2 polyclonal antibody - by Bioz Stars, 2026-02
    90/100 stars

    Images

    1) Product Images from "NRF-2/HO-1 Pathway-Mediated SHOX2 Activation Is a Key Switch for Heart Rate Acceleration by Yixin-Fumai Granules"

    Article Title: NRF-2/HO-1 Pathway-Mediated SHOX2 Activation Is a Key Switch for Heart Rate Acceleration by Yixin-Fumai Granules

    Journal: Oxidative Medicine and Cellular Longevity

    doi: 10.1155/2022/8488269

    siRNA target sequences.
    Figure Legend Snippet: siRNA target sequences.

    Techniques Used: Sequencing

    RT-qPCR primers.
    Figure Legend Snippet: RT-qPCR primers.

    Techniques Used:

    YXFMs thwart CACNA1G reduction within SSS mice SAN. (a) Immunofluorescence staining assay for VSNL1 and CACNA1G (scale = 20 μ m). (b) Western blotting assay for SHOX2. (c, d) Comparative analyses for Western blotting results and fluorescence intensities. ∗∗ P < 0.01 in comparison to the CON group, ## P < 0.01 and # P < 0.05 in comparison to the SSS group. CON: control group; SSS: sick sinus syndrome group; YXFMs: Yixin-Fumai granule-administered group.
    Figure Legend Snippet: YXFMs thwart CACNA1G reduction within SSS mice SAN. (a) Immunofluorescence staining assay for VSNL1 and CACNA1G (scale = 20 μ m). (b) Western blotting assay for SHOX2. (c, d) Comparative analyses for Western blotting results and fluorescence intensities. ∗∗ P < 0.01 in comparison to the CON group, ## P < 0.01 and # P < 0.05 in comparison to the SSS group. CON: control group; SSS: sick sinus syndrome group; YXFMs: Yixin-Fumai granule-administered group.

    Techniques Used: Immunofluorescence, Staining, Western Blot, Fluorescence

    YXFMs activated NRF-2 and improve SHOX2 deficiency in senescent HL-1 cells. (a) DCFH-DA staining for ROS assay (scale = 50 μ m). (b) Immunofluorescence staining for NRF-2 and SHOX2 assay (scale = 10 μ m). (c) Comparative analyses for ROS content. (d) Comparative analyses for the NRF-2 and SHOX2 expression. ∗∗ P < 0.01 and ∗ P < 0.05 in comparison to the CON group, ## P < 0.01 in comparison to the senescence group, △△ P < 0.01 in comparison to the YXFM group. CON: control group; senescence: D-galactose administered group; YXFMs: D-galactose + Yixin-Fumai granule-administered group; YXFMs + ML385: D-galactose + Yixin-Fumai granule + NRF-2 inhibitor ML385-administered group; H 2 O 2 : hydrogen peroxide-administered group.
    Figure Legend Snippet: YXFMs activated NRF-2 and improve SHOX2 deficiency in senescent HL-1 cells. (a) DCFH-DA staining for ROS assay (scale = 50 μ m). (b) Immunofluorescence staining for NRF-2 and SHOX2 assay (scale = 10 μ m). (c) Comparative analyses for ROS content. (d) Comparative analyses for the NRF-2 and SHOX2 expression. ∗∗ P < 0.01 and ∗ P < 0.05 in comparison to the CON group, ## P < 0.01 in comparison to the senescence group, △△ P < 0.01 in comparison to the YXFM group. CON: control group; senescence: D-galactose administered group; YXFMs: D-galactose + Yixin-Fumai granule-administered group; YXFMs + ML385: D-galactose + Yixin-Fumai granule + NRF-2 inhibitor ML385-administered group; H 2 O 2 : hydrogen peroxide-administered group.

    Techniques Used: Staining, ROS Assay, Immunofluorescence, Expressing

    YXFMs improve pulsatile dysfunction in senescent hiPSC-AMs. (a) Field potential traces of hiPSC-AMs. (b, c) Comparative analyses for the beat rate and field potential duration of hiPSC-AMs. ∗∗ P < 0.01 in comparison to the CON group, ## P < 0.01 and # P < 0.05 in comparison to the senescence group, △△ P < 0.01 in comparison to the YXFM group; NS: no statistical significance; CON: control group; senescence: D-galactose administered group; YXFMs: D-galactose + Yixin-Fumai granule-administered group; YXFMs + si-NC: D-galactose + Yixin-Fumai granule-administered + si- NC transfection group; YXFMs + si- SHOX2 : D-galactose + Yixin-Fumai granule-administered + si- SHOX2 transfection group; YXFMs + ML385: D-galactose + Yixin-Fumai granules + NRF2 inhibitor ML385-administered group.
    Figure Legend Snippet: YXFMs improve pulsatile dysfunction in senescent hiPSC-AMs. (a) Field potential traces of hiPSC-AMs. (b, c) Comparative analyses for the beat rate and field potential duration of hiPSC-AMs. ∗∗ P < 0.01 in comparison to the CON group, ## P < 0.01 and # P < 0.05 in comparison to the senescence group, △△ P < 0.01 in comparison to the YXFM group; NS: no statistical significance; CON: control group; senescence: D-galactose administered group; YXFMs: D-galactose + Yixin-Fumai granule-administered group; YXFMs + si-NC: D-galactose + Yixin-Fumai granule-administered + si- NC transfection group; YXFMs + si- SHOX2 : D-galactose + Yixin-Fumai granule-administered + si- SHOX2 transfection group; YXFMs + ML385: D-galactose + Yixin-Fumai granules + NRF2 inhibitor ML385-administered group.

    Techniques Used: Transfection

    YXFMs improve pulsatile function in SHOX2-silenced hiPSC-AMs. (a) Field potential traces of hiPSC-AMs. (b, c) Statistical results for the beat rate and field potential duration of hiPSC-AMs. ∗∗ P < 0.01 in comparison to the si-NC group, ## P < 0.01 and # P < 0.05 in comparison to the si- SHOX2 group, △△ P < 0.01 in comparison to the YXFM group; NS: no statistical significance; CON: control group; si-NC: si-NC transfection group; si- SHOX2 : si- SHOX2 transfection group; YXFMs: si- SHOX2 transfection + Yixin-Fumai granule-administered group; SB4: si- SHOX2 transfection + BMP4 activator SB4-administered group; YXFMs + LDN193189: si- SHOX2 transfection + Yixin-Fumai granule + BMP4 inhibitor LDN193189-administered group. YXFMs + mibefradil: si- SHOX2 transfection + Yixin-Fumai granule + T-type calcium channel inhibitor mibefradil-administered group.
    Figure Legend Snippet: YXFMs improve pulsatile function in SHOX2-silenced hiPSC-AMs. (a) Field potential traces of hiPSC-AMs. (b, c) Statistical results for the beat rate and field potential duration of hiPSC-AMs. ∗∗ P < 0.01 in comparison to the si-NC group, ## P < 0.01 and # P < 0.05 in comparison to the si- SHOX2 group, △△ P < 0.01 in comparison to the YXFM group; NS: no statistical significance; CON: control group; si-NC: si-NC transfection group; si- SHOX2 : si- SHOX2 transfection group; YXFMs: si- SHOX2 transfection + Yixin-Fumai granule-administered group; SB4: si- SHOX2 transfection + BMP4 activator SB4-administered group; YXFMs + LDN193189: si- SHOX2 transfection + Yixin-Fumai granule + BMP4 inhibitor LDN193189-administered group. YXFMs + mibefradil: si- SHOX2 transfection + Yixin-Fumai granule + T-type calcium channel inhibitor mibefradil-administered group.

    Techniques Used: Transfection

    YXFMs increase CACNA1G expression through SHOX2 upregulation. (a) CACNA1G expression in HL-1 cells (scale = 10 μ m). (b) Comparative analyses for RT-qPCR. (c) Comparative analyses for immunofluorescence staining. (d) Western blotting assay for SHOX2, BMP4, GATA4, and NKX2-5 in HL-1 cells. (e) Comparative analyses for Western blotting. ∗∗ P < 0.01 and ∗ P < 0.05 in comparison to the si-NC group, ## P < 0.01 and # P < 0.05 in comparison to the si- Shox2 group. NS: no statistical significance; CON: control group; si-NC: si-NC transfection group; si- Shox2 : si- Shox2 transfection group; YXFMs: si- Shox2 transfection + Yixin-Fumai granule-administered group; SB4: si- Shox2 transfection + BMP4 activator SB4-administered group.
    Figure Legend Snippet: YXFMs increase CACNA1G expression through SHOX2 upregulation. (a) CACNA1G expression in HL-1 cells (scale = 10 μ m). (b) Comparative analyses for RT-qPCR. (c) Comparative analyses for immunofluorescence staining. (d) Western blotting assay for SHOX2, BMP4, GATA4, and NKX2-5 in HL-1 cells. (e) Comparative analyses for Western blotting. ∗∗ P < 0.01 and ∗ P < 0.05 in comparison to the si-NC group, ## P < 0.01 and # P < 0.05 in comparison to the si- Shox2 group. NS: no statistical significance; CON: control group; si-NC: si-NC transfection group; si- Shox2 : si- Shox2 transfection group; YXFMs: si- Shox2 transfection + Yixin-Fumai granule-administered group; SB4: si- Shox2 transfection + BMP4 activator SB4-administered group.

    Techniques Used: Expressing, Quantitative RT-PCR, Immunofluorescence, Staining, Western Blot, Transfection

    The mechanism of YXFMs improving SAN dysfunction: NRF-2/HO-1 pathway-mediated SHOX2 activation is a key switch.
    Figure Legend Snippet: The mechanism of YXFMs improving SAN dysfunction: NRF-2/HO-1 pathway-mediated SHOX2 activation is a key switch.

    Techniques Used: Activation Assay



    Similar Products

    90
    Bioss shox2 polyclonal antibody
    siRNA target sequences.
    Shox2 Polyclonal Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/shox2 polyclonal antibody/product/Bioss
    Average 90 stars, based on 1 article reviews
    shox2 polyclonal antibody - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    90
    Proteintech shox2 and nkx25 polyclonal antibodies
    siRNA target sequences.
    Shox2 And Nkx25 Polyclonal Antibodies, supplied by Proteintech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/shox2 and nkx25 polyclonal antibodies/product/Proteintech
    Average 90 stars, based on 1 article reviews
    shox2 and nkx25 polyclonal antibodies - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    90
    OriGene shox2 rabbit polyclonal antibody
    siRNA target sequences.
    Shox2 Rabbit Polyclonal Antibody, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/shox2 rabbit polyclonal antibody/product/OriGene
    Average 90 stars, based on 1 article reviews
    shox2 rabbit polyclonal antibody - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    90
    Santa Cruz Biotechnology primary goat polyclonal antibody against shox2 sc-21898
    Primers used in reverse transcription-quantitative polymerase chain reaction analyses.
    Primary Goat Polyclonal Antibody Against Shox2 Sc 21898, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary goat polyclonal antibody against shox2 sc-21898/product/Santa Cruz Biotechnology
    Average 90 stars, based on 1 article reviews
    primary goat polyclonal antibody against shox2 sc-21898 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    90
    Santa Cruz Biotechnology polyclonal antibodies shox2, tbx3, cx45, cx43
    Primers used in reverse transcription-quantitative polymerase chain reaction analyses.
    Polyclonal Antibodies Shox2, Tbx3, Cx45, Cx43, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal antibodies shox2, tbx3, cx45, cx43/product/Santa Cruz Biotechnology
    Average 90 stars, based on 1 article reviews
    polyclonal antibodies shox2, tbx3, cx45, cx43 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    98
    Santa Cruz Biotechnology shox2 polyclonal antibody
    Figure 1. <t>SHOX2</t> is a miR-375 target. (A) qRT-PCR analysis of SHOX2 expression in breast cancer cell lines. Data are means ± SEM (n = 3). (B) qRT-PCR analysis of miR-375 expression in breast cancer cell lines. Data are means ± SEM (n = 3). (C) Western blot analyses of SHOX2, E-cadherin, and vimentin expression in breast cancer cell lines. β-Actin was used as control. (D) Western blot analysis was used to analyze the effect of miR-375 on SHOX2 expression. miR-375 was lentivirally introduced into MDA-MB-231 and Hs578T cells, followed by the treatment with or without anti–miR-375. β-Actin was used as control. (E) Representation of miR-375 binding sites in the 3′-UTR of SHOX2 mRNA and the mutations generated in this region. Alphabetical numbers are the relative nucleotide positions in the 3′-UTR of SHOX2 mRNA. (F) pMiR containing SHOX2 3′-UTR with or without mutation in miR-375 targeting site was cotransfected into miR-375– transduced MDA-MB-231 and Hs578T cells for 2 days, followed by the analysis of luciferase activity. Data are means ± SEM (n = 3). #P b .01. *P b .05 versus control.
    Shox2 Polyclonal Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/shox2 polyclonal antibody/product/Santa Cruz Biotechnology
    Average 98 stars, based on 1 article reviews
    shox2 polyclonal antibody - by Bioz Stars, 2026-02
    98/100 stars
      Buy from Supplier

    Image Search Results


    siRNA target sequences.

    Journal: Oxidative Medicine and Cellular Longevity

    Article Title: NRF-2/HO-1 Pathway-Mediated SHOX2 Activation Is a Key Switch for Heart Rate Acceleration by Yixin-Fumai Granules

    doi: 10.1155/2022/8488269

    Figure Lengend Snippet: siRNA target sequences.

    Article Snippet: We purchased VSNL1 polyclonal antibody and AlexaFluor488-conjugated AffiniPure goat anti-chicken IgY from Abcam (USA); SHOX2 Polyclonal Antibody from Bioss (China); NRF-2 polyclonal antibody, CACNA1G polyclonal antibody, and CoraLite488- and CoraLite594-conjugated AffiniPure Goat anti-rabbit IgG from Proteintech (China); and 4% paraformaldehyde, Triton X-100, and antifade mounting medium with DAPI from Beyotime Biotechnology (China).

    Techniques: Sequencing

    RT-qPCR primers.

    Journal: Oxidative Medicine and Cellular Longevity

    Article Title: NRF-2/HO-1 Pathway-Mediated SHOX2 Activation Is a Key Switch for Heart Rate Acceleration by Yixin-Fumai Granules

    doi: 10.1155/2022/8488269

    Figure Lengend Snippet: RT-qPCR primers.

    Article Snippet: We purchased VSNL1 polyclonal antibody and AlexaFluor488-conjugated AffiniPure goat anti-chicken IgY from Abcam (USA); SHOX2 Polyclonal Antibody from Bioss (China); NRF-2 polyclonal antibody, CACNA1G polyclonal antibody, and CoraLite488- and CoraLite594-conjugated AffiniPure Goat anti-rabbit IgG from Proteintech (China); and 4% paraformaldehyde, Triton X-100, and antifade mounting medium with DAPI from Beyotime Biotechnology (China).

    Techniques:

    YXFMs thwart CACNA1G reduction within SSS mice SAN. (a) Immunofluorescence staining assay for VSNL1 and CACNA1G (scale = 20 μ m). (b) Western blotting assay for SHOX2. (c, d) Comparative analyses for Western blotting results and fluorescence intensities. ∗∗ P < 0.01 in comparison to the CON group, ## P < 0.01 and # P < 0.05 in comparison to the SSS group. CON: control group; SSS: sick sinus syndrome group; YXFMs: Yixin-Fumai granule-administered group.

    Journal: Oxidative Medicine and Cellular Longevity

    Article Title: NRF-2/HO-1 Pathway-Mediated SHOX2 Activation Is a Key Switch for Heart Rate Acceleration by Yixin-Fumai Granules

    doi: 10.1155/2022/8488269

    Figure Lengend Snippet: YXFMs thwart CACNA1G reduction within SSS mice SAN. (a) Immunofluorescence staining assay for VSNL1 and CACNA1G (scale = 20 μ m). (b) Western blotting assay for SHOX2. (c, d) Comparative analyses for Western blotting results and fluorescence intensities. ∗∗ P < 0.01 in comparison to the CON group, ## P < 0.01 and # P < 0.05 in comparison to the SSS group. CON: control group; SSS: sick sinus syndrome group; YXFMs: Yixin-Fumai granule-administered group.

    Article Snippet: We purchased VSNL1 polyclonal antibody and AlexaFluor488-conjugated AffiniPure goat anti-chicken IgY from Abcam (USA); SHOX2 Polyclonal Antibody from Bioss (China); NRF-2 polyclonal antibody, CACNA1G polyclonal antibody, and CoraLite488- and CoraLite594-conjugated AffiniPure Goat anti-rabbit IgG from Proteintech (China); and 4% paraformaldehyde, Triton X-100, and antifade mounting medium with DAPI from Beyotime Biotechnology (China).

    Techniques: Immunofluorescence, Staining, Western Blot, Fluorescence

    YXFMs activated NRF-2 and improve SHOX2 deficiency in senescent HL-1 cells. (a) DCFH-DA staining for ROS assay (scale = 50 μ m). (b) Immunofluorescence staining for NRF-2 and SHOX2 assay (scale = 10 μ m). (c) Comparative analyses for ROS content. (d) Comparative analyses for the NRF-2 and SHOX2 expression. ∗∗ P < 0.01 and ∗ P < 0.05 in comparison to the CON group, ## P < 0.01 in comparison to the senescence group, △△ P < 0.01 in comparison to the YXFM group. CON: control group; senescence: D-galactose administered group; YXFMs: D-galactose + Yixin-Fumai granule-administered group; YXFMs + ML385: D-galactose + Yixin-Fumai granule + NRF-2 inhibitor ML385-administered group; H 2 O 2 : hydrogen peroxide-administered group.

    Journal: Oxidative Medicine and Cellular Longevity

    Article Title: NRF-2/HO-1 Pathway-Mediated SHOX2 Activation Is a Key Switch for Heart Rate Acceleration by Yixin-Fumai Granules

    doi: 10.1155/2022/8488269

    Figure Lengend Snippet: YXFMs activated NRF-2 and improve SHOX2 deficiency in senescent HL-1 cells. (a) DCFH-DA staining for ROS assay (scale = 50 μ m). (b) Immunofluorescence staining for NRF-2 and SHOX2 assay (scale = 10 μ m). (c) Comparative analyses for ROS content. (d) Comparative analyses for the NRF-2 and SHOX2 expression. ∗∗ P < 0.01 and ∗ P < 0.05 in comparison to the CON group, ## P < 0.01 in comparison to the senescence group, △△ P < 0.01 in comparison to the YXFM group. CON: control group; senescence: D-galactose administered group; YXFMs: D-galactose + Yixin-Fumai granule-administered group; YXFMs + ML385: D-galactose + Yixin-Fumai granule + NRF-2 inhibitor ML385-administered group; H 2 O 2 : hydrogen peroxide-administered group.

    Article Snippet: We purchased VSNL1 polyclonal antibody and AlexaFluor488-conjugated AffiniPure goat anti-chicken IgY from Abcam (USA); SHOX2 Polyclonal Antibody from Bioss (China); NRF-2 polyclonal antibody, CACNA1G polyclonal antibody, and CoraLite488- and CoraLite594-conjugated AffiniPure Goat anti-rabbit IgG from Proteintech (China); and 4% paraformaldehyde, Triton X-100, and antifade mounting medium with DAPI from Beyotime Biotechnology (China).

    Techniques: Staining, ROS Assay, Immunofluorescence, Expressing

    YXFMs improve pulsatile dysfunction in senescent hiPSC-AMs. (a) Field potential traces of hiPSC-AMs. (b, c) Comparative analyses for the beat rate and field potential duration of hiPSC-AMs. ∗∗ P < 0.01 in comparison to the CON group, ## P < 0.01 and # P < 0.05 in comparison to the senescence group, △△ P < 0.01 in comparison to the YXFM group; NS: no statistical significance; CON: control group; senescence: D-galactose administered group; YXFMs: D-galactose + Yixin-Fumai granule-administered group; YXFMs + si-NC: D-galactose + Yixin-Fumai granule-administered + si- NC transfection group; YXFMs + si- SHOX2 : D-galactose + Yixin-Fumai granule-administered + si- SHOX2 transfection group; YXFMs + ML385: D-galactose + Yixin-Fumai granules + NRF2 inhibitor ML385-administered group.

    Journal: Oxidative Medicine and Cellular Longevity

    Article Title: NRF-2/HO-1 Pathway-Mediated SHOX2 Activation Is a Key Switch for Heart Rate Acceleration by Yixin-Fumai Granules

    doi: 10.1155/2022/8488269

    Figure Lengend Snippet: YXFMs improve pulsatile dysfunction in senescent hiPSC-AMs. (a) Field potential traces of hiPSC-AMs. (b, c) Comparative analyses for the beat rate and field potential duration of hiPSC-AMs. ∗∗ P < 0.01 in comparison to the CON group, ## P < 0.01 and # P < 0.05 in comparison to the senescence group, △△ P < 0.01 in comparison to the YXFM group; NS: no statistical significance; CON: control group; senescence: D-galactose administered group; YXFMs: D-galactose + Yixin-Fumai granule-administered group; YXFMs + si-NC: D-galactose + Yixin-Fumai granule-administered + si- NC transfection group; YXFMs + si- SHOX2 : D-galactose + Yixin-Fumai granule-administered + si- SHOX2 transfection group; YXFMs + ML385: D-galactose + Yixin-Fumai granules + NRF2 inhibitor ML385-administered group.

    Article Snippet: We purchased VSNL1 polyclonal antibody and AlexaFluor488-conjugated AffiniPure goat anti-chicken IgY from Abcam (USA); SHOX2 Polyclonal Antibody from Bioss (China); NRF-2 polyclonal antibody, CACNA1G polyclonal antibody, and CoraLite488- and CoraLite594-conjugated AffiniPure Goat anti-rabbit IgG from Proteintech (China); and 4% paraformaldehyde, Triton X-100, and antifade mounting medium with DAPI from Beyotime Biotechnology (China).

    Techniques: Transfection

    YXFMs improve pulsatile function in SHOX2-silenced hiPSC-AMs. (a) Field potential traces of hiPSC-AMs. (b, c) Statistical results for the beat rate and field potential duration of hiPSC-AMs. ∗∗ P < 0.01 in comparison to the si-NC group, ## P < 0.01 and # P < 0.05 in comparison to the si- SHOX2 group, △△ P < 0.01 in comparison to the YXFM group; NS: no statistical significance; CON: control group; si-NC: si-NC transfection group; si- SHOX2 : si- SHOX2 transfection group; YXFMs: si- SHOX2 transfection + Yixin-Fumai granule-administered group; SB4: si- SHOX2 transfection + BMP4 activator SB4-administered group; YXFMs + LDN193189: si- SHOX2 transfection + Yixin-Fumai granule + BMP4 inhibitor LDN193189-administered group. YXFMs + mibefradil: si- SHOX2 transfection + Yixin-Fumai granule + T-type calcium channel inhibitor mibefradil-administered group.

    Journal: Oxidative Medicine and Cellular Longevity

    Article Title: NRF-2/HO-1 Pathway-Mediated SHOX2 Activation Is a Key Switch for Heart Rate Acceleration by Yixin-Fumai Granules

    doi: 10.1155/2022/8488269

    Figure Lengend Snippet: YXFMs improve pulsatile function in SHOX2-silenced hiPSC-AMs. (a) Field potential traces of hiPSC-AMs. (b, c) Statistical results for the beat rate and field potential duration of hiPSC-AMs. ∗∗ P < 0.01 in comparison to the si-NC group, ## P < 0.01 and # P < 0.05 in comparison to the si- SHOX2 group, △△ P < 0.01 in comparison to the YXFM group; NS: no statistical significance; CON: control group; si-NC: si-NC transfection group; si- SHOX2 : si- SHOX2 transfection group; YXFMs: si- SHOX2 transfection + Yixin-Fumai granule-administered group; SB4: si- SHOX2 transfection + BMP4 activator SB4-administered group; YXFMs + LDN193189: si- SHOX2 transfection + Yixin-Fumai granule + BMP4 inhibitor LDN193189-administered group. YXFMs + mibefradil: si- SHOX2 transfection + Yixin-Fumai granule + T-type calcium channel inhibitor mibefradil-administered group.

    Article Snippet: We purchased VSNL1 polyclonal antibody and AlexaFluor488-conjugated AffiniPure goat anti-chicken IgY from Abcam (USA); SHOX2 Polyclonal Antibody from Bioss (China); NRF-2 polyclonal antibody, CACNA1G polyclonal antibody, and CoraLite488- and CoraLite594-conjugated AffiniPure Goat anti-rabbit IgG from Proteintech (China); and 4% paraformaldehyde, Triton X-100, and antifade mounting medium with DAPI from Beyotime Biotechnology (China).

    Techniques: Transfection

    YXFMs increase CACNA1G expression through SHOX2 upregulation. (a) CACNA1G expression in HL-1 cells (scale = 10 μ m). (b) Comparative analyses for RT-qPCR. (c) Comparative analyses for immunofluorescence staining. (d) Western blotting assay for SHOX2, BMP4, GATA4, and NKX2-5 in HL-1 cells. (e) Comparative analyses for Western blotting. ∗∗ P < 0.01 and ∗ P < 0.05 in comparison to the si-NC group, ## P < 0.01 and # P < 0.05 in comparison to the si- Shox2 group. NS: no statistical significance; CON: control group; si-NC: si-NC transfection group; si- Shox2 : si- Shox2 transfection group; YXFMs: si- Shox2 transfection + Yixin-Fumai granule-administered group; SB4: si- Shox2 transfection + BMP4 activator SB4-administered group.

    Journal: Oxidative Medicine and Cellular Longevity

    Article Title: NRF-2/HO-1 Pathway-Mediated SHOX2 Activation Is a Key Switch for Heart Rate Acceleration by Yixin-Fumai Granules

    doi: 10.1155/2022/8488269

    Figure Lengend Snippet: YXFMs increase CACNA1G expression through SHOX2 upregulation. (a) CACNA1G expression in HL-1 cells (scale = 10 μ m). (b) Comparative analyses for RT-qPCR. (c) Comparative analyses for immunofluorescence staining. (d) Western blotting assay for SHOX2, BMP4, GATA4, and NKX2-5 in HL-1 cells. (e) Comparative analyses for Western blotting. ∗∗ P < 0.01 and ∗ P < 0.05 in comparison to the si-NC group, ## P < 0.01 and # P < 0.05 in comparison to the si- Shox2 group. NS: no statistical significance; CON: control group; si-NC: si-NC transfection group; si- Shox2 : si- Shox2 transfection group; YXFMs: si- Shox2 transfection + Yixin-Fumai granule-administered group; SB4: si- Shox2 transfection + BMP4 activator SB4-administered group.

    Article Snippet: We purchased VSNL1 polyclonal antibody and AlexaFluor488-conjugated AffiniPure goat anti-chicken IgY from Abcam (USA); SHOX2 Polyclonal Antibody from Bioss (China); NRF-2 polyclonal antibody, CACNA1G polyclonal antibody, and CoraLite488- and CoraLite594-conjugated AffiniPure Goat anti-rabbit IgG from Proteintech (China); and 4% paraformaldehyde, Triton X-100, and antifade mounting medium with DAPI from Beyotime Biotechnology (China).

    Techniques: Expressing, Quantitative RT-PCR, Immunofluorescence, Staining, Western Blot, Transfection

    The mechanism of YXFMs improving SAN dysfunction: NRF-2/HO-1 pathway-mediated SHOX2 activation is a key switch.

    Journal: Oxidative Medicine and Cellular Longevity

    Article Title: NRF-2/HO-1 Pathway-Mediated SHOX2 Activation Is a Key Switch for Heart Rate Acceleration by Yixin-Fumai Granules

    doi: 10.1155/2022/8488269

    Figure Lengend Snippet: The mechanism of YXFMs improving SAN dysfunction: NRF-2/HO-1 pathway-mediated SHOX2 activation is a key switch.

    Article Snippet: We purchased VSNL1 polyclonal antibody and AlexaFluor488-conjugated AffiniPure goat anti-chicken IgY from Abcam (USA); SHOX2 Polyclonal Antibody from Bioss (China); NRF-2 polyclonal antibody, CACNA1G polyclonal antibody, and CoraLite488- and CoraLite594-conjugated AffiniPure Goat anti-rabbit IgG from Proteintech (China); and 4% paraformaldehyde, Triton X-100, and antifade mounting medium with DAPI from Beyotime Biotechnology (China).

    Techniques: Activation Assay

    Primers used in reverse transcription-quantitative polymerase chain reaction analyses.

    Journal: Molecular Medicine Reports

    Article Title: Shox2 influences mesenchymal stem cell fate in a co-culture model in vitro

    doi: 10.3892/mmr.2016.5306

    Figure Lengend Snippet: Primers used in reverse transcription-quantitative polymerase chain reaction analyses.

    Article Snippet: The membranes were then incubated with primary goat polyclonal antibody against Shox2 (cat. no. sc-21898, Santa Cruz Biotechnology Inc.; 1:200) and GAPDH (cat. no. sc-48166, Santa Cruz Biotechnology Inc.; 1:200) and rabbit polyclonal antibodies against Tbx3 (cat. no. sc-48781, Santa Cruz Biotechnology Inc.; 1:200), Cx45 (cat. no. sc-25716, Santa Cruz Biotechnology Inc.; 1:200), Cx43 (cat. no. sc-9059, Santa Cruz Biotechnology Inc.; 1:200), HCN4 (cat. no. ab69054, Abcam, Cambridge, UK; 1:100) and Nkx2.5 (cat. no. ab97355, Abcam, UK; 1:500) were incubated separately overnight at 4°C with gentle agitation.

    Techniques: Polymerase Chain Reaction

    Characterization of cMSCs. (A) Laser confocal microscopy of cMSCs after transfection. cMSCs were transfected with pLentis-mShox2-RFP, as evidenced by the expression of Shox2. Nuclei were stained blue with 4′,6-diamidino-2-phenylindole as a control. (B) Fluorescence images of 1:4 cMSCs: RNCMs co-cultured on day 5 after plating. cMSCs were randomly distributed in culture. Scale bar, 50 µ m. (C) Shox2-transfected cMSCs expressing Cx45 were co-cultured with RNCMs. None of the control cells displayed this positive expression. Scale bar, 20 µ m. cMSC, canine mesenchymal stem cells; NRMCs, rat neonatal cardiomyocytes; Shox2, short stature homeobox 2; Cx45, Connexin 45; RFP, red fluorescent protein.

    Journal: Molecular Medicine Reports

    Article Title: Shox2 influences mesenchymal stem cell fate in a co-culture model in vitro

    doi: 10.3892/mmr.2016.5306

    Figure Lengend Snippet: Characterization of cMSCs. (A) Laser confocal microscopy of cMSCs after transfection. cMSCs were transfected with pLentis-mShox2-RFP, as evidenced by the expression of Shox2. Nuclei were stained blue with 4′,6-diamidino-2-phenylindole as a control. (B) Fluorescence images of 1:4 cMSCs: RNCMs co-cultured on day 5 after plating. cMSCs were randomly distributed in culture. Scale bar, 50 µ m. (C) Shox2-transfected cMSCs expressing Cx45 were co-cultured with RNCMs. None of the control cells displayed this positive expression. Scale bar, 20 µ m. cMSC, canine mesenchymal stem cells; NRMCs, rat neonatal cardiomyocytes; Shox2, short stature homeobox 2; Cx45, Connexin 45; RFP, red fluorescent protein.

    Article Snippet: The membranes were then incubated with primary goat polyclonal antibody against Shox2 (cat. no. sc-21898, Santa Cruz Biotechnology Inc.; 1:200) and GAPDH (cat. no. sc-48166, Santa Cruz Biotechnology Inc.; 1:200) and rabbit polyclonal antibodies against Tbx3 (cat. no. sc-48781, Santa Cruz Biotechnology Inc.; 1:200), Cx45 (cat. no. sc-25716, Santa Cruz Biotechnology Inc.; 1:200), Cx43 (cat. no. sc-9059, Santa Cruz Biotechnology Inc.; 1:200), HCN4 (cat. no. ab69054, Abcam, Cambridge, UK; 1:100) and Nkx2.5 (cat. no. ab97355, Abcam, UK; 1:500) were incubated separately overnight at 4°C with gentle agitation.

    Techniques: Confocal Microscopy, Transfection, Expressing, Staining, Control, Fluorescence, Cell Culture

    Shox2, Tbx3, HCN4, Cx45, Nkx2.5 and Cx43 gene expression was examined using reverse transcription-quantitative polymerase chain reaction. Similar results were obtained in three independent experiments. Data are presented as the mean ± standard error of the mean. * P<0.05 vs. control. Shox2, Short stature homeobox 2; Tbx3, T box 3; HCN4, hyperpolarization-activated cyclic nucleotide-gated cation channel; Cx45, connexin 45; Cx43, Connexin 43; RFP, red fluorescent protein; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; RNCMs, rat neonatal cardiomyocytes.

    Journal: Molecular Medicine Reports

    Article Title: Shox2 influences mesenchymal stem cell fate in a co-culture model in vitro

    doi: 10.3892/mmr.2016.5306

    Figure Lengend Snippet: Shox2, Tbx3, HCN4, Cx45, Nkx2.5 and Cx43 gene expression was examined using reverse transcription-quantitative polymerase chain reaction. Similar results were obtained in three independent experiments. Data are presented as the mean ± standard error of the mean. * P<0.05 vs. control. Shox2, Short stature homeobox 2; Tbx3, T box 3; HCN4, hyperpolarization-activated cyclic nucleotide-gated cation channel; Cx45, connexin 45; Cx43, Connexin 43; RFP, red fluorescent protein; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; RNCMs, rat neonatal cardiomyocytes.

    Article Snippet: The membranes were then incubated with primary goat polyclonal antibody against Shox2 (cat. no. sc-21898, Santa Cruz Biotechnology Inc.; 1:200) and GAPDH (cat. no. sc-48166, Santa Cruz Biotechnology Inc.; 1:200) and rabbit polyclonal antibodies against Tbx3 (cat. no. sc-48781, Santa Cruz Biotechnology Inc.; 1:200), Cx45 (cat. no. sc-25716, Santa Cruz Biotechnology Inc.; 1:200), Cx43 (cat. no. sc-9059, Santa Cruz Biotechnology Inc.; 1:200), HCN4 (cat. no. ab69054, Abcam, Cambridge, UK; 1:100) and Nkx2.5 (cat. no. ab97355, Abcam, UK; 1:500) were incubated separately overnight at 4°C with gentle agitation.

    Techniques: Gene Expression, Reverse Transcription, Real-time Polymerase Chain Reaction, Control

    Shox2, Tbx3, HCN4, Cx45, Nkx2.5 and Cx43 protein expression were examined using western blotting. Similar results were obtained in three independent experiments. Shox2, Short stature homeobox 2; Tbx3, T box 3; HCN4, hyperpolarization-activated cyclic nucleotide-gated cation channel; Cx45, connexin 45; Cx43, Connexin 43; RFP, red fluorescent protein; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; RNCMs, rat neonatal cardiomyocytes.

    Journal: Molecular Medicine Reports

    Article Title: Shox2 influences mesenchymal stem cell fate in a co-culture model in vitro

    doi: 10.3892/mmr.2016.5306

    Figure Lengend Snippet: Shox2, Tbx3, HCN4, Cx45, Nkx2.5 and Cx43 protein expression were examined using western blotting. Similar results were obtained in three independent experiments. Shox2, Short stature homeobox 2; Tbx3, T box 3; HCN4, hyperpolarization-activated cyclic nucleotide-gated cation channel; Cx45, connexin 45; Cx43, Connexin 43; RFP, red fluorescent protein; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; RNCMs, rat neonatal cardiomyocytes.

    Article Snippet: The membranes were then incubated with primary goat polyclonal antibody against Shox2 (cat. no. sc-21898, Santa Cruz Biotechnology Inc.; 1:200) and GAPDH (cat. no. sc-48166, Santa Cruz Biotechnology Inc.; 1:200) and rabbit polyclonal antibodies against Tbx3 (cat. no. sc-48781, Santa Cruz Biotechnology Inc.; 1:200), Cx45 (cat. no. sc-25716, Santa Cruz Biotechnology Inc.; 1:200), Cx43 (cat. no. sc-9059, Santa Cruz Biotechnology Inc.; 1:200), HCN4 (cat. no. ab69054, Abcam, Cambridge, UK; 1:100) and Nkx2.5 (cat. no. ab97355, Abcam, UK; 1:500) were incubated separately overnight at 4°C with gentle agitation.

    Techniques: Expressing, Western Blot

    Figure 1. SHOX2 is a miR-375 target. (A) qRT-PCR analysis of SHOX2 expression in breast cancer cell lines. Data are means ± SEM (n = 3). (B) qRT-PCR analysis of miR-375 expression in breast cancer cell lines. Data are means ± SEM (n = 3). (C) Western blot analyses of SHOX2, E-cadherin, and vimentin expression in breast cancer cell lines. β-Actin was used as control. (D) Western blot analysis was used to analyze the effect of miR-375 on SHOX2 expression. miR-375 was lentivirally introduced into MDA-MB-231 and Hs578T cells, followed by the treatment with or without anti–miR-375. β-Actin was used as control. (E) Representation of miR-375 binding sites in the 3′-UTR of SHOX2 mRNA and the mutations generated in this region. Alphabetical numbers are the relative nucleotide positions in the 3′-UTR of SHOX2 mRNA. (F) pMiR containing SHOX2 3′-UTR with or without mutation in miR-375 targeting site was cotransfected into miR-375– transduced MDA-MB-231 and Hs578T cells for 2 days, followed by the analysis of luciferase activity. Data are means ± SEM (n = 3). #P b .01. *P b .05 versus control.

    Journal: Neoplasia (New York, N.Y.)

    Article Title: SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells.

    doi: 10.1016/j.neo.2014.03.010

    Figure Lengend Snippet: Figure 1. SHOX2 is a miR-375 target. (A) qRT-PCR analysis of SHOX2 expression in breast cancer cell lines. Data are means ± SEM (n = 3). (B) qRT-PCR analysis of miR-375 expression in breast cancer cell lines. Data are means ± SEM (n = 3). (C) Western blot analyses of SHOX2, E-cadherin, and vimentin expression in breast cancer cell lines. β-Actin was used as control. (D) Western blot analysis was used to analyze the effect of miR-375 on SHOX2 expression. miR-375 was lentivirally introduced into MDA-MB-231 and Hs578T cells, followed by the treatment with or without anti–miR-375. β-Actin was used as control. (E) Representation of miR-375 binding sites in the 3′-UTR of SHOX2 mRNA and the mutations generated in this region. Alphabetical numbers are the relative nucleotide positions in the 3′-UTR of SHOX2 mRNA. (F) pMiR containing SHOX2 3′-UTR with or without mutation in miR-375 targeting site was cotransfected into miR-375– transduced MDA-MB-231 and Hs578T cells for 2 days, followed by the analysis of luciferase activity. Data are means ± SEM (n = 3). #P b .01. *P b .05 versus control.

    Article Snippet: They include SHOX2 polyclonal antibody (kindly provided by Dr Yi-Ping Chen at Tulane University, New Orleans, LA), Vimentin mAb (Santa Cruz Biotechnology, Santa Cruz, CA, CatalogNo. sc-6260), E-cadherin monolyclonal antibody (BD Biosciences, San Jose, CA, Catalog No. 610405), β-Actin mAb (Santa Cruz Biotechnology, Catalog DAPI E Control SHOX2 DAPI Control SHOX2 A B Figure W1.

    Techniques: Quantitative RT-PCR, Expressing, Western Blot, Control, Binding Assay, Generated, Mutagenesis, Luciferase, Activity Assay

    Figure 2. miR-375 suppresses EMT by diminishing SHOX2 expression. (A) Western blot analysis was used to determine the effect of ectopic SHOX2 expression on E-cadherin and vimentin expression. β-Actin was used as control. (B) Matrigel invasion assay was used to analyze the effect of ectopic SHOX2 expression on in vitro invasion of miR-375–trasduced MDA-MB-231 and Hs578T cells. Data are means ± SEM (n = 3). #P b .05. *P b .05 versus miR-control. (C) qRT-PCR was used to determine the effect of SHOX2 knockdown on E-cadherin and vimentin expression. Data are means ± SEM (n = 3). *P b .05 versus shControl. (D) Western blot analysis was used to determine the effect of SHOX2 knockdown on E-cadherin and vimentin expression. β-Actin was used as control. (E) Morphologies of control and SHOX2 knockdown MDA-MB-231 and Hs578T cells. (F) Transwell migration assay was used to analyze the effect of SHOX2 knockdown on cell motility. Data are means ± SEM (n = 3). *P b .05 versus shControl.

    Journal: Neoplasia (New York, N.Y.)

    Article Title: SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells.

    doi: 10.1016/j.neo.2014.03.010

    Figure Lengend Snippet: Figure 2. miR-375 suppresses EMT by diminishing SHOX2 expression. (A) Western blot analysis was used to determine the effect of ectopic SHOX2 expression on E-cadherin and vimentin expression. β-Actin was used as control. (B) Matrigel invasion assay was used to analyze the effect of ectopic SHOX2 expression on in vitro invasion of miR-375–trasduced MDA-MB-231 and Hs578T cells. Data are means ± SEM (n = 3). #P b .05. *P b .05 versus miR-control. (C) qRT-PCR was used to determine the effect of SHOX2 knockdown on E-cadherin and vimentin expression. Data are means ± SEM (n = 3). *P b .05 versus shControl. (D) Western blot analysis was used to determine the effect of SHOX2 knockdown on E-cadherin and vimentin expression. β-Actin was used as control. (E) Morphologies of control and SHOX2 knockdown MDA-MB-231 and Hs578T cells. (F) Transwell migration assay was used to analyze the effect of SHOX2 knockdown on cell motility. Data are means ± SEM (n = 3). *P b .05 versus shControl.

    Article Snippet: They include SHOX2 polyclonal antibody (kindly provided by Dr Yi-Ping Chen at Tulane University, New Orleans, LA), Vimentin mAb (Santa Cruz Biotechnology, Santa Cruz, CA, CatalogNo. sc-6260), E-cadherin monolyclonal antibody (BD Biosciences, San Jose, CA, Catalog No. 610405), β-Actin mAb (Santa Cruz Biotechnology, Catalog DAPI E Control SHOX2 DAPI Control SHOX2 A B Figure W1.

    Techniques: Expressing, Western Blot, Control, Invasion Assay, In Vitro, Quantitative RT-PCR, Knockdown, Transwell Migration Assay

    Figure 3. SHOX2 induces EMT traits in epithelial-like breast cancer cells. (A) qRT-PCR was used to determine the effect of ectopic SHOX2 expression on E-cadherin and vimentin expression. Data are means ± SEM (n = 3). #P b .01 versus Control. *P b .05 versus Control. (B) Western blot analysis was used to determine the effect of ectopic SHOX2 expression on E-cadherin and vimentin expression. β-Actin was used as control. (C) Morphologies of control and SHOX2-transduced MCF7 and T47D cells. (D) Transwell migration assay was used to analyze the effect of ectopic SHOX2 expression on cell motility. Data are means ± SEM (n = 3). *P b .05 versus Control.

    Journal: Neoplasia (New York, N.Y.)

    Article Title: SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells.

    doi: 10.1016/j.neo.2014.03.010

    Figure Lengend Snippet: Figure 3. SHOX2 induces EMT traits in epithelial-like breast cancer cells. (A) qRT-PCR was used to determine the effect of ectopic SHOX2 expression on E-cadherin and vimentin expression. Data are means ± SEM (n = 3). #P b .01 versus Control. *P b .05 versus Control. (B) Western blot analysis was used to determine the effect of ectopic SHOX2 expression on E-cadherin and vimentin expression. β-Actin was used as control. (C) Morphologies of control and SHOX2-transduced MCF7 and T47D cells. (D) Transwell migration assay was used to analyze the effect of ectopic SHOX2 expression on cell motility. Data are means ± SEM (n = 3). *P b .05 versus Control.

    Article Snippet: They include SHOX2 polyclonal antibody (kindly provided by Dr Yi-Ping Chen at Tulane University, New Orleans, LA), Vimentin mAb (Santa Cruz Biotechnology, Santa Cruz, CA, CatalogNo. sc-6260), E-cadherin monolyclonal antibody (BD Biosciences, San Jose, CA, Catalog No. 610405), β-Actin mAb (Santa Cruz Biotechnology, Catalog DAPI E Control SHOX2 DAPI Control SHOX2 A B Figure W1.

    Techniques: Quantitative RT-PCR, Expressing, Control, Western Blot, Transwell Migration Assay

    Figure 4. SHOX2 induces EMT through TGFβ signaling network. (A) Effect of LY364947 on morphologies of control and SHOX2- transduced MCF7 and T47D cells. (B) Western blot analysis was used to determine the effect of LY364947 on E-cadherin and vimentin expression in control and SHOX2-transduced MCF7 and T47D cells. β-Actin was used as control. (C) qRT-PCR was used to determine the effect of ectopic SHOX2 expression on TβR-I, TβR-II, and TβR-III expression in MCF7 and T47D cells. Data are means ± SEM (n = 3). *, P b .05 versus Control. (D) Western blot analysis was used to determine the effect of ectopic SHOX2 expression on TβR-I, TβR-II, and TβR-III expression in MCF7 and T47D cells. (E) qRT-PCR was used to determine the effect of SHOX2 knockdown on TβR-I, TβR-II, and TβR- III expression in MDA-MB-231 and Hs578T cells. Data are means ± SEM (n = 3). *P b .05 versus shControl. (F) Western blot analysis was used to determine the effect of SHOX2 knockdown on TβR-I, TβR-II, and TβR-III expression in MDA-MB-231 and Hs578T cells.

    Journal: Neoplasia (New York, N.Y.)

    Article Title: SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells.

    doi: 10.1016/j.neo.2014.03.010

    Figure Lengend Snippet: Figure 4. SHOX2 induces EMT through TGFβ signaling network. (A) Effect of LY364947 on morphologies of control and SHOX2- transduced MCF7 and T47D cells. (B) Western blot analysis was used to determine the effect of LY364947 on E-cadherin and vimentin expression in control and SHOX2-transduced MCF7 and T47D cells. β-Actin was used as control. (C) qRT-PCR was used to determine the effect of ectopic SHOX2 expression on TβR-I, TβR-II, and TβR-III expression in MCF7 and T47D cells. Data are means ± SEM (n = 3). *, P b .05 versus Control. (D) Western blot analysis was used to determine the effect of ectopic SHOX2 expression on TβR-I, TβR-II, and TβR-III expression in MCF7 and T47D cells. (E) qRT-PCR was used to determine the effect of SHOX2 knockdown on TβR-I, TβR-II, and TβR- III expression in MDA-MB-231 and Hs578T cells. Data are means ± SEM (n = 3). *P b .05 versus shControl. (F) Western blot analysis was used to determine the effect of SHOX2 knockdown on TβR-I, TβR-II, and TβR-III expression in MDA-MB-231 and Hs578T cells.

    Article Snippet: They include SHOX2 polyclonal antibody (kindly provided by Dr Yi-Ping Chen at Tulane University, New Orleans, LA), Vimentin mAb (Santa Cruz Biotechnology, Santa Cruz, CA, CatalogNo. sc-6260), E-cadherin monolyclonal antibody (BD Biosciences, San Jose, CA, Catalog No. 610405), β-Actin mAb (Santa Cruz Biotechnology, Catalog DAPI E Control SHOX2 DAPI Control SHOX2 A B Figure W1.

    Techniques: Control, Western Blot, Expressing, Quantitative RT-PCR, Knockdown

    Figure 5. SHOX2 transcriptionally regulates TβR-I expression. (A) Effect of SHOX2 knockdown on TβR-I promoter activity in MDA-MB-231 and Hs578T cells. Data are means ± SEM (n = 3). #P b .01 versus shControl. (B) Effect of ectopic SHOX2 expression on TβR-I promoter activity in MCF7 and T47D cells. Data are means ± SEM (n = 3). #P b .01 versus Control. (C) Effect of mutation in putative SHOX2-binding site on TβR-I promoter activity in MDA-MB-231 and Hs578T cells or SHOX2-induced TβR-I promoter activity in MCF7 and T47D cells. Data are means ± SEM (n = 3). #P b .01 versus wild-type (WT) or SHOX2 (−). (D) FLAG-SHOX2-transduced MDA-MB-231 cells were subjected to ChIP with FLAG mAb or mouse IgG. Quantitative PCR (qPCR) was performed using a primer set that amplifies various regions in TβR-I promoter. Data are means ± SEM (n = 3). *P b .05 versus Control (mouse IgG).

    Journal: Neoplasia (New York, N.Y.)

    Article Title: SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells.

    doi: 10.1016/j.neo.2014.03.010

    Figure Lengend Snippet: Figure 5. SHOX2 transcriptionally regulates TβR-I expression. (A) Effect of SHOX2 knockdown on TβR-I promoter activity in MDA-MB-231 and Hs578T cells. Data are means ± SEM (n = 3). #P b .01 versus shControl. (B) Effect of ectopic SHOX2 expression on TβR-I promoter activity in MCF7 and T47D cells. Data are means ± SEM (n = 3). #P b .01 versus Control. (C) Effect of mutation in putative SHOX2-binding site on TβR-I promoter activity in MDA-MB-231 and Hs578T cells or SHOX2-induced TβR-I promoter activity in MCF7 and T47D cells. Data are means ± SEM (n = 3). #P b .01 versus wild-type (WT) or SHOX2 (−). (D) FLAG-SHOX2-transduced MDA-MB-231 cells were subjected to ChIP with FLAG mAb or mouse IgG. Quantitative PCR (qPCR) was performed using a primer set that amplifies various regions in TβR-I promoter. Data are means ± SEM (n = 3). *P b .05 versus Control (mouse IgG).

    Article Snippet: They include SHOX2 polyclonal antibody (kindly provided by Dr Yi-Ping Chen at Tulane University, New Orleans, LA), Vimentin mAb (Santa Cruz Biotechnology, Santa Cruz, CA, CatalogNo. sc-6260), E-cadherin monolyclonal antibody (BD Biosciences, San Jose, CA, Catalog No. 610405), β-Actin mAb (Santa Cruz Biotechnology, Catalog DAPI E Control SHOX2 DAPI Control SHOX2 A B Figure W1.

    Techniques: Expressing, Knockdown, Activity Assay, Control, Mutagenesis, Binding Assay, Real-time Polymerase Chain Reaction

    Figure 6. SHOX2 is functionally associated with breast tumorigenicity. (A) Univariate survival method (Kaplan-Meier method) of patients with breast cancer indicates a strong correlation between SHOX expression and recurrence-free survival (P = .041; log-rank test). (B) Univariate survival method (Kaplan-Meier method) of patients with breast cancer indicates a strong correlation between SHOX expression and overall survival (P = .041; log-rank test). (C) Multivariate survival analysis (proportional hazards method) shows a positive, independent prognostic importance of SHOX2 expression (P b .05; likelihood ratio test), in addition to the independent prognostic impact of lymph node status and PGR positivity. HR, hazard ratio. (D) Effect of ectopic SHOX2 expression on in vitro invasion of MCF7 and T47D cells. Data are means ± SEM (n = 3). *P b .05 versus Control. (E) Effect of SHOX2 knockdown on in vitro invasion of MDA-MB-231 and Hs578T cells. Data are means ± SEM (n = 3). *P b .05 versus shControl. (F) Effect of SHOX2 knockdown on in vivo dissemination of MDA- MB-231 in zebrafish. (G) Effect of ectopic SHOX2 expression on in vivo dissemination of T47D in zebrafish.

    Journal: Neoplasia (New York, N.Y.)

    Article Title: SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells.

    doi: 10.1016/j.neo.2014.03.010

    Figure Lengend Snippet: Figure 6. SHOX2 is functionally associated with breast tumorigenicity. (A) Univariate survival method (Kaplan-Meier method) of patients with breast cancer indicates a strong correlation between SHOX expression and recurrence-free survival (P = .041; log-rank test). (B) Univariate survival method (Kaplan-Meier method) of patients with breast cancer indicates a strong correlation between SHOX expression and overall survival (P = .041; log-rank test). (C) Multivariate survival analysis (proportional hazards method) shows a positive, independent prognostic importance of SHOX2 expression (P b .05; likelihood ratio test), in addition to the independent prognostic impact of lymph node status and PGR positivity. HR, hazard ratio. (D) Effect of ectopic SHOX2 expression on in vitro invasion of MCF7 and T47D cells. Data are means ± SEM (n = 3). *P b .05 versus Control. (E) Effect of SHOX2 knockdown on in vitro invasion of MDA-MB-231 and Hs578T cells. Data are means ± SEM (n = 3). *P b .05 versus shControl. (F) Effect of SHOX2 knockdown on in vivo dissemination of MDA- MB-231 in zebrafish. (G) Effect of ectopic SHOX2 expression on in vivo dissemination of T47D in zebrafish.

    Article Snippet: They include SHOX2 polyclonal antibody (kindly provided by Dr Yi-Ping Chen at Tulane University, New Orleans, LA), Vimentin mAb (Santa Cruz Biotechnology, Santa Cruz, CA, CatalogNo. sc-6260), E-cadherin monolyclonal antibody (BD Biosciences, San Jose, CA, Catalog No. 610405), β-Actin mAb (Santa Cruz Biotechnology, Catalog DAPI E Control SHOX2 DAPI Control SHOX2 A B Figure W1.

    Techniques: Expressing, In Vitro, Control, Knockdown, In Vivo